Portal de Periódicos da CAPES

Single-centre, triple-blinded, randomised, 1-year, parallel-group, superiority study to compare the effects of Roux-en-Y gastric bypass and sleeve gastrectomy on remission of type 2 diabetes and β-cell function in subjects with morbid obesity: a protocol for the Obesity s urg e ry in Tøns berg ( O seberg) study

2019; BMJ; Volume: 9; Issue: 6 Linguagem: Inglês

10.1136/bmjopen-2018-024573

2044-6055

Heidi Borgeraas, Jøran Hjelmesæth, Kåre I. Birkeland, Farhat Fatima, John Olav Grimnes, Hanne L. Gulseth, Erling Halvorsen, Jens Kristoffer Hertel, Tor Olav Widerøe Hillestad, Line Kristin Johnson, Tor‐Ivar Karlsen, Ronette L. Kolotkin, Nils Petter Kvan, Morten Lindberg, Jolanta Lorentzen, Njord Nordstrand, Rune Sandbu, Kathrine Aagelen Seeberg, Birgitte Seip, Marius Svanevik, Tone Gretland Valderhaug, Dag Hofsø,

Obesity and Health Practices

Introduction Bariatric surgery is increasingly recognised as an effective treatment option for subjects with type 2 diabetes and obesity; however, there is no conclusive evidence on the superiority of Roux-en-Y gastric bypass or sleeve gastrectomy. The Oseberg study was designed to compare the effects of gastric bypass and sleeve gastrectomy on remission of type 2 diabetes and β-cell function. Methods and analysis Single-centre, randomised, triple-blinded, two-armed superiority trial carried out at the Morbid Obesity Centre at Vestfold Hospital Trust in Norway. Eligible patients with type 2 diabetes and obesity were randomly allocated in a 1:1 ratio to either gastric bypass or sleeve gastrectomy. The primary outcome measures are (1) the proportion of participants with complete remission of type 2 diabetes (HbA1c≤6.0% in the absence of blood glucose-lowering pharmacologic therapy) and (2) β-cell function expressed by the disposition index (calculated using the frequently sampled intravenous glucose tolerance test with minimal model analysis) 1 year after surgery. Ethics and dissemination The protocol of the current study was reviewed and approved by the regional ethics committee on 12 September 2012 (ref: 2012/1427/REK sør-øst B). The results will be disseminated to academic and health professional audiences and the public via publications in international peer-reviewed journals and conferences. Participants will receive a summary of the main findings. Trial registration number NCT01778738 ;Pre-results.